Research & Development

HitGen to acquire fragment and structure-based biotech company Vernalis

HitGen announces it has entered into a definitive agreement with Ligand Pharmaceuticals to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment and structure-based drug discovery research.

Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines

Molecular engineering company Scribe Therapeutics has entered into a research collaboration with Biogen for the development of CRISPR-based genetic medicines for neurological diseases.

Bristol Myers Squibb to buy biopharmaceutical firm MyoKardia for $13.1bn

Bristol Myers Squibb (BMS) has signed an agreement to acquire clinical-stage biopharmaceutical company MyoKardia for $13.1bn.

Covis Group to buy AMAG Pharmaceuticals for $498m

Covis Group has agreed to acquire US-based commercial-stage biopharmaceutical company AMAG Pharmaceuticals for about $498m on a fully diluted basis.

Pfizer to acquire minority stake in CStone Pharmaceuticals for $200m

Pfizer has announced an equity investment of $200m to purchase a 9.90% stake in biopharmaceutical company CStone Pharmaceuticals.

Orgenesis to acquire regenerative medicine company Koligo Therapeutics

Biotechnology company Orgenesis has signed an agreement to acquire US-based regenerative medicine company Koligo Therapeutics.

Permira funds to acquire European CNS specialty pharmaceutical company Neuraxpharm

Permira, the global private equity firm, today announced that a company backed by the Permira funds has agreed to acquire Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners.

OnKure, Pfizer collaborate to evaluate combination of OKI-179 and binimetinib

OnKure, a leader in discovery and development of next generation histone deacetylase (HDAC) inhibitors, entered into a clinical trial collaboration and supply agreement with Pfizer to support the clinical proof of concept study for MEKTOVI (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma.

Roche acquires Irish biotechnology company Inflazome for €380m

Swiss drugmaker Roche has completed a share purchase agreement to acquire an Irish biotechnology company Inflazome for an upfront payment of €380m.